SWORD Health Stock

swordhealth.comHealthcare / Healthcare providers & servicesFounded: 2014Funding to Date: $294.86MM

Sword Health, founded in 2014, is an online platform focused on preventing, managing, and treating pain through digital physical therapy at accessible costs. Sword’s platform combines their proprietary artificial intelligence with sensor technology delivering live feedback that can be shared with a therapist remotely.

Register To Buy and Sell Shares

For more details on financing and valuation for SWORD Health, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access SWORD Health’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like SWORD Health.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Virgílio Bento Ph.D
Co-Founder, Chief Executive Officer & Chairman
Valentina Longo
Chief Financial Officer
Márcio Colunas
Co-Founder, Chief Technology Officer, CSO & Board Member
Jason Richards
Chief Information Security Officer & Vice President of Security & Information Security
Beth Stevens
Chief Legal Officer
Michael Krueger
Chief Marketing Officer
Kyle Spackman
Chief Commercial Officer

Board Members

Dave Guilmette
Todd Cozzens Ph.D
Transformation Capital

Frequently Asked Questions About SWORD Health’s Stock

Can you buy SWORD Health’s stock?
SWORD Health is not publicly traded on NYSE or NASDAQ in the U.S. To buy SWORD Health’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell SWORD Health’s stock?
Yes, you can sell stock of a private company like SWORD Health. Forge can help you sell your SWORD Health stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is SWORD Health’s stock price?
SWORD Health is a privately held company and therefore does not have a public stock price. However, you may access SWORD Health’s private market stock price with Forge Data.
What is SWORD Health’s stock ticker symbol?
SWORD Health does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Sword Health Strategy: Focusing on AI Ahead of a Potential IPO
Sword Health, a physical therapy start-up, is strategically focusing on artificial intelligence ahead of a potential IPO. The company aims to triple its AI team and is open to making acquisitions to spur growth. CEO Virgilio Bento plans to take the company public after it achieves profitability, which is expected in 2024.
How This Founder is Working to Free 2 Billion People from Pain
Growing up, Virgilio Bento watched his older brother suffer an accident and struggle to access the intensive physical therapy he needed to recover. Bento has since dedicated his career to solving pain for the two billion people around the globe who suffer each year. In 2015, he started Sword Health to free the world from pain and has helped thousands of people along the way.
European tech companies are leading the fight against debilitating and chronic pain
Aspect Biosystems and Novo Nordisk are collaborating on a $2.6 billion project to develop therapeutics for type 1 diabetes and obesity. The companies aim to create 3D, biologically functional tissues containing insulin-producing cells that can be implanted without the need for immunosuppressive drugs. The partnership will fund up to four products for the treatment of diabetes and/or obesity, with Aspect eligible to receive up to $650 million per project based on future milestones, plus royalties on product sales.
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.